Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Designed to assess the impact of CardiolRx on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application. Data from Cardiol’s…

Read More

RUA GOLD Expands High-Grade Intercepts at Depth at Auld Creek: 5.9g/t AuEq over 9m and 48.3g/t AuEq over 1.25m

Rua Gold Inc. (TSXV: RUA) (OTCQB: NZAUF) (WKN: A40QYC) (‘Rua Gold’ or the ‘Company’) is pleased to provide an update on its gold-antimony exploration at the Auld Creek project in the Reefton Goldfield on the South Island of New Zealand, reporting improved gold grades from current drilling in diamond drillholes ACDDH026, ACDDH027, ACDDH028. Highlights: Following…

Read More

SAGA Metals Completes Maiden Drill Program and Commences Further Geophysics at the Radar Project

Saga Metals Corp. (‘SAGA’ or the ‘Company’) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company focused on critical mineral discovery, announces the final batch of core from the Company’s maiden drill program at the Radar Titanium-Vanadium (Ti-V) project has been shipped for analysis to Activation Laboratories in Ancaster, Ontario. The 2,200m of…

Read More

AMENDED FROM SOURCE – Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TSX Venture Exchange: BSK Frankfurt Stock Exchange: MAL2 Blue Sky Uranium Corp. (TSXV: BSK) (FSE: MAL2) (‘Blue Sky’ or the ‘Company’) is pleased to announce that due to continued strong demand, the Company has increased the non-brokered private placement…

Read More
Back To Top